PubMed
RU 58841, a new specific topical antiandrogen: a candidate for the treatment of androgenetic alopecia
Miyamoto et al., 1997
RU58841
Topical anti-androgen research compound discussed for hair-loss protocols (non-peptide).
Overall check-ins
Trackers & reports
Overview
Topical anti-androgen research compound discussed for hair-loss protocols (non-peptide).
Community
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Research
PubMed
Miyamoto et al., 1997
PubMed
Pan et al., 1998
PubMed
Ye et al., 1997
Tools
More ways to learn about RU-58841 from observational PeptIQ data.
Compare with
Related peptides
Help
This page summarizes 6 anonymized self-reports from PeptIQ users who track RU-58841, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. RU-58841 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
This wiki summarizes observational community reports and linked citations for RU-58841. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for RU-58841 for study-level context — not medical advice.
RU-58841 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
Safety data quality for RU-58841 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
This page links 3 indexed sources for RU-58841. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.